Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : APB-R3
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Evommune
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Evommune Secures Rights to Develop Phase 2-ready IL-18 Fusion Protein From AprilBio
Details : Through the license agreement, Evommune will research, develop & commercialize EVO301 (APB-R3), a long-acting injectable fusion protein that is designed for inflammation.
Brand Name : EVO301
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 24, 2024
Lead Product(s) : APB-R3
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Evommune
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?